When it comes to financial risk, it's difficult to be too vigilant considering the long-term damage done to the global economy since the financial crisis. Certainly, it is a good thing when regulators prove that they are on task, keeping a watchful eye on all things financial in an effort to keep the economy on an even keel.
The recent rumblings regarding mortgage REITs, and their possible negative impact on the economy, is a case in point. How much of a risk do these entities really pose to the financial system, with what some consider their high leverage and expanding asset base?
Putting things in perspective
Perhaps in response to such concerns, hybrid mREIT Two Harbors (NYSE: TWO ) recently released a useful investor primer on the industry, giving a much clearer view of just where mREITs stand compared to other mortgage players.
The primer notes that, by far, commercial banks, the Federal Reserve, and government sponsored entities like Fannie and Freddie hold most of the U.S. mortgage debt, with mREITs ranking No. 7 out of nine categories. Additionally, of the $600 billion of market capitalization occupied by the REIT industry as a whole, mortgage REITs come in at a little under 10%,�at $59 billion.
Top 10 Chemical Stocks To Watch Right Now: ENSCO plc(ESV)
Ensco plc, together with its subsidiaries, provides offshore contract drilling services to the oil and gas industry. The company engages in the drilling of offshore oil and natural gas wells by providing its drilling rigs and crews under contracts with international, government-owned, and independent oil and gas companies. As of February 15, 2010, it owned and operated 42 jackup rigs, 4 ultra-deepwater semisubmersible rigs, and 1 barge rig. The company also has 4 ultra-deepwater semisubmersible rigs under construction. It operates in Asia, the Middle East, Australia, New Zealand, Europe, Africa, and North and South America. The company was formerly known as Ensco International plc and changed its name to Ensco plc in March 2010. Ensco plc was founded in 1975 and is based in London, the United Kingdom.
Advisors' Opinion:- [By Double Dividend Stocks]
London-based Ensco plc, (ESV), provides offshore contract drilling services to the oil and gas industry worldwide, and operates a drilling rig fleet of approximately 74 rigs, including 9 drill ships, 13 dynamically positioned semisubmersible rigs, 6 moored semisubmersible rigs, and 46 jackup rigs. ESV currently has the world's second largest offshore rig fleet, behind only Transocean, which has 95 rigs, and just ahead of Noble, (NE), which has 73 rigs. Ensco has the newest fleet of Ultradeepwater rigs, with 3, and, has 4 more on order, which are already contracted.
- [By Ben Levisohn]
We do not see an immediate inflection in group sentiment but see an opportunity in getting paid to wait for a market recovery. Our favorite yield plays include [Seadrill, Seadrill Partners, and North Atlantic Drilling.] Meanwhile, we would stick to premium asset exposure ([Atwood Oceanics (ATW), Ensco (ESV), Pacific Drilling (PACD]) over lower- end fleets ([Diamond Offshore Drilling (DO), Noble (NE), Transocean (RIG)]).
- [By Tyler Crowe]
In the rig industry, Ensco (NYSE: ESV ) has been trying very hard to do its best impersonation of the top ultra-deepwater driller,�Seadrill (NYSE: SDRL ) . It has a young fleet of vessels that can be used in the most extreme water depths today, and it is garnering top dollar for these assets. Still, there are still a few things setting Seadrill apart from Ensco among our favorite energy stocks in 2013.�
- [By John Buckingham, Chief Investment Officer, Al Frank Asset Management, Inc. (AFAM)]
Ensco PLC (ESV) is the world's second largest offshore driller. The firm operates across six continents with one of the newest jackup and deepwater fleets in the contract drilling industry.
Best Dow Dividend Stocks To Watch Right Now: Ishares Msci Australia Inc (EWA)
iShares MSCI Australia Index Fund (the Fund) seeks to provide investment results that correspond generally to the price and yield performance of publicly traded securities in the aggregate in the Australian market, as measured by the MSCI Australia Index (the Index). The Index seeks to measure the performance of the Australian equity market. The Index is a capitalization-weighted index that aims to capture 85% of the (publicly available) total market capitalization. Component companies are adjusted for available float and must meet objective criteria for inclusion in the Index. The Index is reviewed quarterly.
The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. The Fund�� investment advisor is Barclays Global Fund Advisors.
Advisors' Opinion:- [By Chad Fraser]
Another option is to buy units of an Australian exchange traded fund (ETF) like the iShares MSCI Australia Index Fund (NYSE: EWA), one of the investments we cover in Australian Edge’s How They Rate universe, which keeps over 100 Australian companies and other investments under continuous review.
Best Dow Dividend Stocks To Watch Right Now: AstraZeneca PLC (AZN)
AstraZeneca PLC (AstraZeneca), incorporated on June 17, 1992, is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments for illnesses, such as its antibiotic, Merrem/Meronem and Losec/Prilosec for acid related diseases. AstraZeneca�� products include Crestor, Atacand,Seloken/Toprol-XL, Plendil, Onglyza, Zestril, Symbicort and Zoladex. The Company owns and operates a range of research and development (R&D), production and marketing facilities worldwide. AstraZeneca operates in over 100 countries, including China, Mexico, Brazil and Russia. On August 31, 2011, the Company completed the sale of the Astra Tech business to DENTSPLY International Inc. On June 19, 2012, the Company acquired Ardea Biosciences Inc (Ardea), a biotechnology company in San Diego, California. In July 2012, the Company acquired a portfolio of neuroscience assets from Link Medicine Corporation. In August 2012, Alliance Pharma plc�� wholly owned subsidiary, Alliance Pharmaceuticals Limited, acquired the antimalarial brands Paludrine, Avloclor and Savarine from AstraZeneca UK Limited. In August 2012, the Company and Bristol-Myers Squibb Company announced the acquisition of Amylin Pharmaceuticals, Inc. by Bristol-Myers Squibb Company. In June 2013, the Company acquired Pearl Therapeutics.
Cardiovascular
The Company�� marketed products include Crestor (rosuvastatin calcium), Atacand2 (candesartan cilexetil), Seloken/Toprol-XL (metoprolol succinate), Tenormin (atenolol), Plendil (felodipine), Zestril3 (lisinopril dihydrate), Brilinta/Brilique (ticagrelor), and Axanum, (acetylsalicylic acid (ASA). Crestor1 is a statin used for the treatment of dyslipidaemia and hypercholesterolemia. In some markets, it is also indicated to slow the progression of atherosclerosis and to re! duce the risk of first cardiovascular (CV) events. Atacand2 is an angiotensin II antagonist used for the 1st line treatment of hypertension and symptomatic heart failure. Seloken/Toprol-XL is a beta-blocker once-daily tablet used for 24-hour control of hypertension and for use in heart failure and angina.
Tenormin is a cardioselective beta-blocker used for hypertension, angina pectoris and other CV disorders. Plendil is a calcium antagonist used for the treatment of hypertension and angina. Zestril3 is an angiotensin-converting enzyme inhibitor used for the treatment of a wide range of CV diseases, including hypertension. Brilinta/Brilique is an oral antiplatelet for the treatment of acute coronary syndromes (ACS). Axanum is a fixed dose combination indicated for prevention of CV events in high-risk CV patients in need of daily low-dose ASA treatment and who are at risk of gastric ulcers.
The Company�� marketed products for diabetes include Komboglyze ((saxagliptin and metformin HCl), Kombiglyze XR (saxagliptin and metformin XR) and Onglyza (saxagliptin). Komboglyze is an immediate release fixed dose combination indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with Type 2 diabetes mellitus inadequately controlled on their maximally tolerated dose of metformin alone or those already being treated with the combination of saxagliptin and metformin as separate tablets. Kombiglyze XR is an extended release fixed dose combination indicated as an adjunct to diet and exercise to improve glycaemic control in adults with Type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate. Onglyza is a DPP-IV inhibitor used for the treatment of Type 2 diabetes.
Gastrointestinal
AstraZeneca�� marketed products include Nexium (esomeprazole), Losec/Prilosec (omeprazole) and Entocort (budesonide). Nexium is a proton pump inhibitor (PPI) used for the treatment of acid-related diseases to offer clini! cal impro! vements over other PPIs and other treatments. Losec/Prilosec is used for the short-term and long-term treatment of acid-related diseases. Entocort is a corticosteroid used for the treatment of inflammatory bowel disease. Nexium is marketed in approximately 120 countries and is available in oral (tablet/capsules and oral suspension) and intravenous (i.v.) dosage forms for the treatment of acid-related diseases.
Infection
The Company�� marketed products include Merrem/Meronem (meropenem), Cubicin (daptomycin) and FluMist/Fluenz (influenza vaccine live, intranasal). Merrem/Meronem is a carbapenem anti-bacterial used for the treatment of serious infections in hospitalised patients. Cubicin is a cyclic lipopeptide anti-bacterial used for the treatment of serious infections in hospitalised patients. FluMist/Fluenz is an intranasal live, attenuated, trivalent influenza vaccine.
Neuroscience
AstraZeneca�� marketed products include Seroquel IR (quetiapine fumarate), Seroquel XR (an extended release formulation of quetiapine fumarate), Zomig (zolmitriptan), Diprivan (propofol), Vimovo (naproxen/esomeprazole magnesium), Naropin (ropivacaine), Xylocaine (lidocaine) and EMLA (lidocaine and prilocaine). Seroquel IR is an atypical anti-psychotic drug used for the treatment of schizophrenia and bipolar disorder (mania, depression and maintenance). Seroquel XR is used for the treatment of schizophrenia, bipolar disorder, MDD and in some territories for generalised anxiety disorder (GAD).
Zomig is used for the treatment of migraines with or without aura and Zomig Nasal Spray is indicated for the acute treatment of cluster. Diprivan is an intravenous general anaesthetic used in the induction and maintenance of general anaesthesia, for use in intensive care sedation and conscious sedation for surgical as well as diagnostic procedures. Vimovo is a fixed-dose combination of enteric-coated naproxen (an NSAID) with the gastroprotection of immediate release ! esomepraz! ole (a proton pump inhibitor) for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, and to decrease the developing of gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. Naropin is used as a long-acting local anaesthetic, for surgical anaesthesia and acute pain management. Xylocaine is a used short-acting local anaesthetic. EMLA is used as a local anaesthetic for topical application.
Oncology
AstraZeneca�� marketed products include Arimidex (anastrozole), Zoladex (goserelin acetate implant), Casodex (bicalutamide), Iressa (gefitinib), Faslodex (fulvestrant), Nolvadex (tamoxifen citrate) and Caprelsa (vandetanib). Arimidex is an aromatase inhibitor used for the treatment of early breast cancer. Zoladex, in one- and three-month depots, is a luteinising hormone-releasing hormone agonist used for the treatment of prostate cancer, breast cancer and certain benign gynaecological disorders. Casodex is an anti-androgen therapy used for the treatment of prostate cancer.
Advisors' Opinion:- [By Max Macaluso, Ph.D.]
Early Tuesday morning, Rigel Pharmaceuticals� (NASDAQ: RIGL ) and its now-ex-partner, AstraZeneca (NYSE: AZN ) , reported late-stage clinical trial results for the experimental rheumatoid arthritis drug Fostamatinib. In the following video, health-care analyst Max Macaluso discusses why Rigel dropped 18% after the news was released and the risks that lie ahead for Rigel Pharmaceuticals.
Best Dow Dividend Stocks To Watch Right Now: Honeywell International Inc.(HON)
Honeywell International Inc. operates as a diversified technology and manufacturing company worldwide. Its Aerospace segment provides turbine propulsion engines, auxiliary power units, environmental control and electric power systems, engine systems and accessories, avionic systems, aircraft lighting, inertial sensors, control products, space products and subsystems, and landing products for aircraft manufacturers, airlines, business and general aviation, military, space, and airport operations, as well as offers management and technical, logistics, aircraft wheels and brakes and repair, and overhaul services. The company?s Automation and Control Solutions segment provides environmental and combustion controls, and sensing controls; security and life safety products and services; scanning and mobility products; process automation products and solutions; and building solutions and services for homes, buildings, and industrial facilities. Its Specialty Materials segment prov ides resins and chemicals; hydrofluoric acid; fluorocarbons; fluorine specialties; nuclear services; performance chemicals; chemical processing sealants; fibers and composites; specialty films and additives; imaging and electronic chemicals; semiconductor materials and services; catalysts, adsorbents, and specialties; and renewable fuels and chemicals. It offers these products for refining, petrochemical, automotive, healthcare, agricultural, packaging, refrigeration, appliance, housing, semiconductor, wax, and adhesives segments. This segment also provides process technology and equipment for the petroleum refining, and petrochemical and gas processing industries. The company?s Transportation Systems segment provides charge-air systems; thermal systems; filters, spark plugs, electronic components, and car care products; and brake hard parts and other friction materials for passenger cars and commercial vehicles. The company was founded in 1920 and is headquartered in Morris Township, New Jersey.
Advisors' Opinion:- [By Monica Gerson]
Honeywell International (NYSE: HON) is projected to report its Q3 earnings at $1.24 per share on revenue of $9.92 billion.
Ingersoll-Rand Plc (NYSE: IR) is estimated to report its Q3 earnings at $1.10 per share on revenue of $3.73 billion.
- [By Alyce Lomax]
So far in the voting tallies this proxy season, majority approval is nowhere to be found for these proposals agitating for independent chairs. However, at some companies, the votes in favor are creeping closer. A few of the impressive favorable tallies this year: IBM (NYSE: IBM ) (44%), Honeywell (NYSE: HON ) �(43%), and Boeing (NYSE: BA ) (42%). Venturing that close to the 50% mark is a big deal when shareholder votes on topics like these hardly added up to a blip on the radar years ago.
No comments:
Post a Comment